Get notified when ODTX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Critical incident detected

Existential event

Time-sensitive event — see the red-flag panel below for the source-quoted detail.

Red Flags Detected

  • Going Concern (new) — Management has concluded there is substantial doubt about the company's ability to continue as a going concern.
  • Material Weakness (new) — The company recently remediated a material weakness in its internal control over financial reporting.
NASDAQ: ODTX Odyssey Therapeutics, Inc. S-1/A

Odyssey Therapeutics files for IPO, plans to offer 13.24M shares at $17.00 each, raising $225.1M gross

Filed May 4, 2026 · ~2 min read

Key Changes

  • high

    Odyssey plans to sell 13,240,000 shares at $17.00 per share, raising $225.1M gross for the company; net proceeds to the company are $23.3M.

    The Offering verify on EDGAR →
  • high

    The company will not receive proceeds from the concurrent private placement of 1,470,588 shares to TPG Orazio II, an existing stockholder affiliate.

    The Offering verify on EDGAR →
  • high

    Odyssey reported a GAAP net loss of $148.6 million for 2025, up from $129.3 million in 2024.

    Risk Factors verify on EDGAR →

4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MCFT 10-K) is open in full — no account needed.

Partner

Trade ODTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 31, 2026 · How we verify